Evogene (EVGN) Company Report

Evogene Ltd.'s subsidiary, Biomica Ltd., and Shanghai Lishan Biopharmaceuticals Co., Ltd. have entered into an exclusive worldwide licensing agreement for BMC128.
BMC128 is a first-in-class microbiome-based therapeutic, currently completing a Phase 1 clinical study, designed to enhance anti-tumor immune activity in renal cell carcinoma and non-small cell lung cancer.
Under the agreement, Lishan Biotech will assume responsibility for global clinical development, manufacturing, and commercialization of BMC128, while Biomica will be eligible to receive development milestone payments and royalties on future commercial sales.
Lishan Biotech plans to advance BMC128 into a Phase 2 clinical study and pursue regulatory filings in both China and the United States.

2 days ago

Press Release

Evogene's Subsidiary Biomica Enters Licensing Agreement for BMC128

EVGN

New Projects/Investments

Evogene's subsidiary, Biomica Ltd., and Shanghai Lishan Biopharmaceuticals Co., Ltd. (Lishan Biotech) announced an exclusive worldwide licensing agreement for BMC128, a microbiome-based therapeutic designed to enhance anti-tumor immune activity.
BMC128, developed by Biomica, is currently completing a Phase 1 clinical study for renal cell carcinoma and non-small cell lung cancer, showing promising early clinical results.
Under the agreement, Lishan Biotech will assume responsibility for global clinical development, manufacturing, and commercialization of BMC128, with plans to advance it into a Phase 2 clinical study.
Biomica will be eligible to receive development milestone payments and royalties on future commercial sales.

3 days ago

6-K

Evogene's Subsidiary Biomica Licenses BMC128 to Shanghai Lishan Biopharmaceuticals

EVGN

New Projects/Investments

Evogene's subsidiary, Biomica, has entered into an exclusive worldwide licensing agreement with Shanghai Lishan Biopharmaceuticals Co., Ltd. for BMC128.
BMC128 is a first-in-class microbiome-based therapeutic designed to enhance anti-tumor immune activity, currently completing a Phase 1 clinical study for renal cell carcinoma and non-small cell lung cancer.
Under the agreement, Lishan Biotech will assume responsibility for global clinical development, manufacturing, and commercialization of BMC128, with plans to advance it into a Phase 2 clinical study.
Biomica will be eligible to receive development milestone payments and royalties on future commercial sales.

3 days ago

Press Release

EverGen Infrastructure Announces Record Q4 2025 RNG Production

EVGN

New Projects/Investments

Executive Compensation

EverGen Infrastructure Corp. announced record Renewable Natural Gas (RNG) production for the quarter ending December 31, 2025.
Corporate RNG production in Q4 2025 reached 54,480 GJ.
The company granted an aggregate of 1,200,000 restricted share units (RSUs) to officers and directors on January 23, 2026, and an additional 40,000 RSUs to an officer on December 17, 2025.

Jan 29, 2026, 2:00 PM

Press Release

EverGen Infrastructure Closes FCC Credit Facility and Private Placement

EVGN

Debt Issuance

New Projects/Investments

EverGen Infrastructure's subsidiary, Fraser Valley Biogas Ltd. (FVB), closed a $13.0 million term loan and a $250,000 operating line of credit with Farm Credit Canada (FCC).
The term loan proceeds will primarily be used to repay $12.0 million of the Company's corporate debt facilities, reducing the remaining balance to approximately $1.1 million, which is expected to materially reduce annual debt service costs.
The Company also closed the second tranche of a non-brokered private placement for gross proceeds of approximately $1.9 million, issuing 3,152,441 common shares at a price of $0.60 per share.
These Refinancing Transactions are a significant step in EverGen's strategic repositioning, strengthening its financial foundation, improving alignment of financing with operating cash flows, and increasing near-term financial flexibility for organic growth and optimization projects.

Jan 16, 2026, 12:46 AM

Press Release

EverGen Infrastructure Updates Debt Refinancing and Private Placement

EVGN

Debt Issuance

New Projects/Investments

EverGen Infrastructure, through its wholly owned subsidiary Fraser Valley Biogas, entered into a Credit Agreement with Farm Credit Canada for a $13 million term loan and a $250,000 operating line of credit.
This new debt facility is intended to repay a majority of the company's corporate debt, with closing and funding expected in the coming days.
The company is extending the second tranche of its non-brokered private placement to raise up to an additional $2,000,000 by issuing up to 3,333,334 Common Shares at $0.60 per share.
The first tranche of this offering closed on May 21, 2025, raising $5,000,000.
Proceeds from the private placement will be used to pay certain outstanding indebtedness, for working capital, and general corporate purposes.

Jan 13, 2026, 4:49 AM

Press Release

Evogene Undergoes Strategic Shift to AI-Driven Computational Chemistry, Reports Q3 2025 Financials

EVGN

Earnings

New Projects/Investments

Layoffs

Evogene is undergoing a strategic transition to establish itself as a leader in computational chemistry, focusing on generative AI (Campus AI) for small molecule design in the pharmaceutical and agriculture industries.
The company implemented an organizational change and cost reduction plan, which led to total operating expenses net of approximately $2.9 million in Q3 2025, a significant decrease from $6.6 million in the same period of 2024.
The sale of the majority of Lavie Bio's activities to ICL in July 2025, along with the sale of Microboost AI for Ag, generated an income of approximately $7.9 million in Q3 2025, contributing to a net income of approximately $5.2 million for the quarter, compared to a net loss of $8.2 million in Q3 2024.
As of September 30, 2025, the company's cash and short-term bank deposit balance was approximately $16 million. Revenues for the nine months ending September 30, 2025, were approximately $3.5 million, down from $4 million in the prior year.

Nov 20, 2025, 2:00 PM

Transcript

Evogene Reports Q3 2025 Net Income Amid Strategic Shift and Asset Sales

EVGN

Earnings

New Projects/Investments

Layoffs

Evogene reported a net income of approximately $5.2 million for Q3 2025, a significant improvement from a net loss of $8.2 million in the same period last year, primarily due to income from discontinued operations and decreased operating expenses.
The company is undergoing a strategic transition to become a leader in computational chemistry, focusing on the generative design of small molecules for the pharmaceutical and agriculture industries, utilizing its Campus AI platform. This shift included a cost reduction plan, with Q3 2025 total operating expenses net of approximately $2.9 million, down from $6.6 million in Q3 2024.
As of September 30, 2025, Evogene's cash and short-term bank deposit balance was approximately $16 million, bolstered by the sale of Lavie Bio's assets and Microboost AI for Ag to ICL, which generated approximately $7.9 million in income during Q3 2025.
For the nine months ending September 30, 2025, revenues were approximately $3.5 million, a decrease from $4 million in the same period last year, mainly due to lower revenue from AgPlenus activities, which included a one-time payment from Bayer during the first quarter of 2024.

Nov 20, 2025, 2:00 PM

Transcript

Evogene Reports Q3 2025 Financial Results and Strategic Transition Progress

EVGN

Earnings

New Projects/Investments

M&A

Evogene reported a net income of approximately $5.2 million for the third quarter ended September 30, 2025, a significant improvement compared to a net loss of approximately $8.2 million in the same period last year, primarily driven by income from discontinued operations, net, of approximately $7.9 million from the sale of Lavie Bio's assets and MicroBoost AI for Ag to ICL.
Revenues for the third quarter of 2025 were approximately $0.3 million, a decrease compared to approximately $1.7 million in the same period of 2024, mainly due to reduced seed sales generated by Casterra and lower revenue from AgPlenus activities.
Total operating expenses, net, for the third quarter of 2025 decreased to approximately $2.9 million from approximately $6.6 million in the same period of 2024, reflecting the impact of an organizational realignment and cost-reduction plan.
As of September 30, 2025, Evogene held consolidated cash, cash equivalents, and short-term bank deposits of approximately $16.0 million. The company is also advancing its strategic transition toward computational chemistry, focusing on the generative design of small molecules.

Nov 20, 2025, 12:00 PM

6-K

Evogene Reports H1 2025 Financials, Strategic Restructuring, and Divestitures

EVGN

Earnings

M&A

Layoffs

Evogene reported revenues of approximately $3.2 million for the six months ended June 30, 2025, an increase from $2.3 million in the prior year, while its overall loss decreased by 21.4% to approximately $7.7 million.
The company is undergoing a strategic shift, focusing on its ChemPass AI tech-engine, which includes integrating AgPlenus's activities into Evogene and implementing workforce reductions of 40% at AgPlenus and 30% at Evogene, with the full effect expected in the second half of 2025.
On July 8, 2025, Evogene completed the sale of most of Lavie Bio's activities and the MicroBoost AI Tech-Engine for agriculture to an ICL affiliate for a total consideration of approximately $18.714 million.
As of June 30, 2025, Evogene held approximately $11.9 million in cash and cash equivalents and short-term bank deposits, which management believes will be sufficient to meet projected cash requirements for at least the next 12 months.
A 1-for-10 reverse share split was effected after market close on July 24, 2024, retroactively adjusting all share and per share amounts presented.